Skip to content

A Study on Predictors of Treatment Response to Sofosbuvir and Ribavirin Therapy in Patients with genotype 2 Chronic Hepatitis C Virus Infection

A Study on Predictors of Treatment Response to Sofosbuvir and Ribavirin Therapy in Patients with genotype 2 Chronic Hepatitis C Virus Infection - Predictor of treatment response to SOF /RBV therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000018947
Enrollment
260
Registered
2015-09-08
Start date
2015-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with genotype 2 HCV infection

Interventions

None listed

Sponsors

Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients (1) with the target disease who (2) satisfy all the inclusion criteria and (3) meet none of the exclusion criteria are eligible for the study. (1) Subjects Patients with a chronic HCV infection and compensated cirrhosis who are being treated as outpatients or inpatients at institutions participating in this study (2) Inclusion criteria [1] Patients who are 20 years of age or older at the time of informed consent [2] Patients who have been fully informed and have provided written informed consent to participate in this study prior to study initiation [3] Patients with a chronic HCV genotype 2 infection and compensated cirrhosis who do not meet any of the following exclusion criteria

Exclusion criteria

Exclusion criteria: 1 Patients with poorly controlled cardiac disease; e.g. myocardial infarction, cardiac failure, arrhythmia 2 Patients with severe hepatic impairment 3 Patients with a history of hypersensitivity to HCV NS5B inhibitors or Ribavirin 4 Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment 5 Patients deemed unsuitable for Study entry by their treating physician 6 Patients with severe renal dysfunction

Design outcomes

Primary

MeasureTime frame
To investigate the predictors obtained at baseline and affecting the sustained virologic response (SVR) rate/occurrence of adverse drug reactions at follow-up Week 12

Secondary

MeasureTime frame
Effects of HCV NS5B mutations as viral factors on virologic response 2) Rate of emergence of drug-resistant variants 3) Presence or absence of a reversal of liver fibrosis 4) Presence or absence of an improvement in AFP levels 5) Effects of glucose/lipid-related factors on treatment response 6) Incidence of AEs

Countries

Japan

Contacts

Public ContactGoki Suda

Hokkaido University Department of Gastroenterology and Hepatology, Graduate School of Medicine,

gsudgast@pop.med.hokudai.ac.jp+81-11-716-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026